Phion

Phion Therapeutics is a biotechnology company based in Belfast, Northern Ireland, specializing in the development of a proprietary peptide-based drug delivery platform. The company's core technology, the RALA peptide, is a 30-amino acid amphipathic peptide that spontaneously forms nanoparticles when mixed with anionic cargo such as mRNA, siRNA, or DNA. This platform is designed to overcome significant hurdles in nucleic acid delivery, including endosomal escape and systemic toxicity, by facilitating efficient intracellular transport. Phion's internal pipeline focuses on oncology and inflammatory conditions, with lead programs targeting HPV-associated cancers and ovarian cancer. By providing a versatile and non-toxic alternative to lipid nanoparticles, Phion aims to enable the next generation of precision genomic medicines.